| Item type |
学術雑誌論文 / Journal Article_02(1) |
| 公開日 |
2012-07-02 |
| タイトル |
|
|
タイトル |
Polaprezinc prevents ongoing thioacetamide-induced liver fibrosis in rats. |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Zinc |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Fibrosis |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Polaprezinc |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Cirrhosis |
| キーワード |
|
|
主題Scheme |
Other |
|
キーワード |
Amino acid complex |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| 著者 |
河野, 透
Asama, Toshiyuki
Chisato, Naoyuki
Ebisawa, Yoshiaki
Okayama, Taishi
Imai, Koji
Karasaki, Hidenori
Furukawa, Hiroyuki
Yoneda, Masashi
|
| 書誌情報 |
Life Sciences
巻 90,
号 3-4,
p. 122-130,
発行日 2012-01-01
|
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0024-3205 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.lfs.2011.10.022 |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Aims: Cirrhotic patients commonly have a liver zinc deficiency, which may aggravate liver fibrosis due to the lack of antioxidative effects of zinc. This study examined the ability of polaprezinc, N-(3-aminopropionyl)-Lhistidinato zinc, to prevent fibrosis in a rat model of thioacetamide (TAA)-induced hepatic fibrosis. Main methods: Liver cirrhosis was induced by orally administering TAA for 20 weeks. The rats were cotreated with one of the following for the last 10 weeks of TAA treatment: (1) polaprezinc (50 or 200 mg/kg/day); (2) L-carnosine (155 mg/kg/day),which contained equal amounts of L-carnosine as 200 mg/kg/day polaprezinc; (3) zinc sulfate (112 mg/kg/day) or (4) zinc-L-aspartic complex (317.8 mg/kg/day). Both zinc supplementations contained equal amounts of zinc as high-dose polaprezinc. Key findings: Hepatic zinc levels fell significantly in rats treated with TAA for 20 weeks. Cotreating with high-dose polaprezinc and zinc-L-aspartic complex for 10 weeks prevented hepatic zinc loss. Hepatic hydroxyproline and tissue inhibitor of metalloproteinases-1 (TIMP-1) were significantly higher in rats treated with TAA for 20 weeks than 10 weeks, whereas polaprezinc prevented changes in these fibrosis markers and reduced hepatic transforming growth factor-β1 protein concentration, macroscopic and histologic changes. TAA caused oxidative stress-related changes in the liver that were prevented by high-dose polaprezinc and partially by zinc-L-aspartic complex. Treatment with L-carnosine, low-dose polaprezinc or zinc sulfate for 10 weeks did not affect liver fibrosis progression or oxidative stress-related changes. Significance: Polaprezincmay prevent ongoing fibrosis by preventing zinc depletion, oxidative stress and fibrosis markers in cirrhotic livers. |
|
言語 |
en |
| 注記 |
|
|
内容記述タイプ |
Other |
|
注記 |
Author |
| 資源タイプ |
|
|
内容記述タイプ |
Other |
|
資源タイプ |
text |
| 著者版フラグ |
|
|
出版タイプ |
AM |
| フォーマット |
|
|
内容記述タイプ |
Other |
|
内容記述 |
application/pdf |
| ID(XooNIps) |
|
|
|
22100444 |
| 閲覧数(XooNIps) |
|
| ダウンロード数(XooNIps) |
|
|
|
1387 |
4639.pdf (1.7 MB)
